BRUIN CLL-322: A phase 3 open-label, randomized study of fixed-duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress) Meeting Abstract
| Authors: | Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; Woyach, J.; Eyre, T. A.; Mato, A. R. |
| Abstract Title: | BRUIN CLL-322: A phase 3 open-label, randomized study of fixed-duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress) |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | cll; chronic lymphocytic leukemia; venetoclax; pirtobrutinib; trial-in-progress; btki; bcl2i |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S267 |
| Language: | English |
| ACCESSION: | WOS:000897948100204 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01325-8 |
| Notes: | Meeting Abstract: CLL-116 -- Source: Wos |
